You are here: Home:Audio Program Guide: BCU Surgeons 2 | 2006 Audio: BCU Surgeons 2 | 2006     Go to interview with Monica Morrow, MD Go to interview with Kevin R Fox, MD Go to interview with Thomas B Julian, MD Go to interview with Robert W Carlson, MD Go to interview with Richard M Elledge, MD   To listen to individual tracks, click the on the track you wish to listen to. To download tracks, right-click on the one you wish to download.       Monica Morrow, MD Professor of Surgery Temple University School of Medicine Chairman, Department of Surgical Oncology G Willing Pepper Chair in Cancer Research Fox Chase Cancer Center Philadelphia, Pennsylvania     Click here to download the entire interview   Track 1 Introduction Track 2 Patients’ misperceptions about the benefits of mastectomy versus breast-conserving surgery Track 3 Improvements in local recurrence rates for patients undergoing breast-conserving surgery Track 4 Potential benefits and preliminary experience with partial breast irradiation Track 5 Differences between surgeons’ and patients’ views on breast-conserving surgery Track 6 False-negative rate of sentinel lymph node biopsy (SLNB) Track 7 Factors influencing the false-negative rate of SLNB Track 8 Clinical use of the Oncotype DX™ assay Track 9 Case discussion: A 48-year-old perimenopausal woman with node-negative, ER-positive disease whose tumor was assayed by Oncotype DX Track 10 Counseling patients about the role of Oncotype DX Track 11 Selection of adjuvant systemic therapy Track 12 Tolerability and efficacy of aromatase inhibitors versus tamoxifen       Kevin R Fox, MD Director, Rena Rowan Breast Center Associate Professor of Medicine University of Pennsylvania Cancer Center Philadelphia, Pennsylvania     Click here to download the entire interview   Track 1 Introduction Track 2 Ovarian suppression concurrent with adjuvant chemotherapy to preserve ovarian functioning Track 3 SWOG trial of chemotherapy with or without ovarian suppression for patients with ER-negative disease Track 4 Potential rationale for the failure of ovarian suppression during chemotherapy to preserve fertility Track 5 Ovarian function after chemotherapy Track 6 Ovarian stimulation, egg recovery, fertilization and cryopreservation to preserve fertility Track 7 Effect of pregnancy on risk of recurrence in patients with previously treated breast cancer Track 8 Importance of barrier contraception during chemotherapy Track 9 Impact of tamoxifen and chemotherapy on fetal outcomes during pregnancy Track 10 Safety of radiation or blue dye exposure for a fetus during SLNB Track 11 Clinical trials of adjuvant hormonal therapy for premenopausal patients Track 12 Utility of ovarian suppression in combination with chemotherapy and tamoxifen Track 13 Implications of data from adjuvant aromatase inhibitor trials for clinical practice Track 14 Selection of optimal up-front hormonal therapy for postmenopausal patients Track 15 Aromatase inhibitors for women with chemotherapy-induced amenorrhea Track 16 Future clinical research questions regarding patients with ER-positive, PR-positive tumors       Thomas B Julian, MD Associate Professor, Human Oncology Drexel University College of Medicine Associate Director, Breast Care Center Allegheny Cancer Center Pittsburgh, Pennsylvania     Click here to download the entire interview   Track 1 Introduction Track 2 NSABP-B-32: Sentinel node biopsy with or without axillary node dissection Track 3 Impact of preoperative biopsy technique on SLNB false-negative rate Track 4 Injection techniques to improve SLNB Track 5 Incidence of paresthesia associated with SLNB Track 6 Completion of axillary dissection after positive SLNB Track 7 Development, importance and clinical use of the Oncotype DX assay Track 8 Utility of Oncotype DX to facilitate decision-making regarding adjuvant chemotherapy Track 9 NSABP-B-35: Anastrozole versus tamoxifen for DCIS Track 10 Tolerability of aromatase inhibitors versus tamoxifen Track 11 Background and rationale for current and future NSABP neoadjuvant trials       Robert W Carlson, MD Professor of Medicine Division of Oncology and Stanford Medical Informatics Stanford University Medical Center Stanford, California     Click here to download the entire interview   Track 1 Introduction Track 2 Selection of up-front adjuvant hormonal therapy for postmenopausal patients Track 3 Clinical use of biomarkers in selecting adjuvant hormonal therapy Track 4 Aromatase inhibitors and ovarian suppression for premenopausal patients with ER-positive disease Track 5 Effectiveness of LHRH agonists in suppressing ovarian function Track 6 Evolution of the clinical role of the Oncotype DX assay Track 7 Adjuvant chemotherapy for patients with ER-positive tumors       Richard M Elledge, MD Medical Director, Breast Care Center Associate Professor of Medicine Baylor College of Medicine Houston, Texas     Click here to download the entire interview   Track 1 Introduction Track 2 Utility and benefit of the Oncotype DX assay Track 3 Case discussion: A 72-year-old woman with ER-positive, PR-positive, node-negative breast cancer Track 4 Use of Oncotype DX to facilitate decision-making about adjuvant chemotherapy Track 5 Quality control in ER and HER2 testing Track 6 Importance of obtaining accurate ER and HER2 status   Search Our Site

Terms and Conditions of Use and General Disclaimer Copyright © 2006 Research To Practice, All Rights Reserved